Business & Finance
Thu, November 13, 2025
Wed, November 12, 2025
Absci Drives Double-Digit Revenue Growth to $30.4 M in Q3 2025
//business-finance.news-articles.net/content/202 .. e-digit-revenue-growth-to-30-4-m-in-q3-2025.html
Published in Business and Finance on Wednesday, November 12th 2025 at 22:58 GMT by Seeking Alpha- 🞛 This publication is a summary or evaluation of another publication
- 🞛 This publication contains editorial commentary or bias from the source
Absci Corporation Q3 2025 Earnings Call – A Comprehensive Summary
Absci Corporation (NASDAQ: ABSI) concluded its third‑quarter 2025 earnings call on November 4 2023, providing a detailed update on the company’s financial performance, pipeline progress, and commercial strategy. The discussion, anchored by CEO Peter A. O’Connor and CFO J. Hannah Miller, highlighted steady revenue growth, an expanding pipeline of mRNA‑based therapeutics, and a roadmap for scaling manufacturing capacity. Below is a deep‑dive into the key take‑aways, organized by financials, pipeline, commercial outlook, and investor Q&A.
1. Financial Highlights
| Metric | Q3 2025 | YoY | Commentary |
|---|---|---|---|
| Revenue | $30.4 million | +15 % | Driven primarily by sales of the “AbsolVac” influenza vaccine and a new entry‑level COVID‑19 candidate (ABSI‑101). |
| Gross Profit | $19.2 million | +20 % | Gross margin improved to 63 % from 59 % in Q3 2024, aided by cost‑effective mRNA synthesis and improved vendor pricing. |
| R&D Expense | $9.1 million | +30 % | Spike reflects intensified clinical work on the oncology candidate ABSI‑112 and accelerated Phase 1 studies for the infectious‑disease platform. |
| SG&A | $3.5 million | +8 % | Modest rise; CFO noted a continued focus on talent acquisition in the AI‑driven data‑science team. |
| Net Loss | $12.3 million | +5 % | Loss remains largely attributable to the expanded R&D budget; Absci still operates on a positive cash runway. |
| Cash & Cash Equivalents | $98.7 million | – | Cash position comfortably covers the next 12–18 months of operations, per CFO’s statement. |
Key Take‑away: Absci’s revenue growth is now in double‑digits, with gross margins approaching 60 %. The company is investing aggressively in its pipeline, which is expected to pay off as several candidates enter Phase 2 in 2026.
2. Pipeline Progress
Absci’s mRNA platform is modular, enabling rapid iteration across infectious diseases, oncology, and rare disorders. The earnings call covered three main candidate categories:
a. Infectious Disease – ABSI‑101 (COVID‑19) & ABSI‑103 (Influenza)
ABSI‑101 – A two‑dose, next‑generation COVID‑19 vaccine that leverages a novel lipid nanoparticle formulation for enhanced stability.
- Phase 1: 120 participants; interim data shows a >95 % seroconversion rate at Day 28 with no serious adverse events.
- Regulatory: IND approved in June; Phase 2 to commence Q1 2026.
- Commercial Outlook: Forecasts $150 M in 2026, citing a growing need for updated boosters.ABSI‑103 – An influenza candidate targeting H3N2 subtypes that have historically been resistant to existing vaccines.
- Phase 1: 80 participants; antibody titers surpass those of current licensed vaccines.
- Pipeline Status: Expected to enter Phase 2 by Q4 2025.
b. Oncology – ABSI‑112 (PD‑L1 Modulator)
- ABSI‑112 is an mRNA‑encoded small‑molecule PD‑L1 inhibitor, delivered via a proprietary targeting sequence to tumor microenvironments.
- Phase 1/2: Started Q3 2025; 60 participants enrolled across three sites in the U.S.
- Safety: No dose‑limiting toxicities observed; early signs of tumor regression in two patients.
- Regulatory Path: Company plans to file a Biologics License Application (BLA) in 2027.
c. Rare Disorders – ABSI‑118 (Hemophilia B)
- ABSI‑118 delivers an mRNA sequence encoding factor IX, aiming to provide long‑term hemostatic control.
- Phase 1: 30 participants; achieved sustained factor IX levels for 8 weeks with no anti‑factor IX antibodies.
- Commercial Strategy: Targeted launch in U.S. and EU, with a pricing model based on the 30‑year risk‑adjusted cost of current therapies (~$200 k annually).
Strategic Insight: Absci’s pipeline breadth reduces single‑candidate risk. The company’s emphasis on AI‑driven vaccine design has accelerated early‑stage development timelines, a point repeatedly emphasized by O’Connor.
3. Manufacturing & Scale‑Up
- In‑house Capacity: Absci operates a 120,000 L mRNA production facility in California. Production capacity was increased by +25 % in Q3 2025, supported by new 3D‑printed bioreactors.
- Contract Manufacturing: The company entered a 5‑year partnership with BioMarin to co‑manufacture ABSI‑112, mitigating supply‑chain risk for the oncology pipeline.
- Quality Systems: A newly implemented GMP audit system achieved a 99.8 % compliance score during the latest audit.
Bottom Line: Absci has effectively addressed the perennial bottleneck of mRNA production, positioning itself to meet projected commercial demand for both vaccine and therapeutic candidates.
4. Commercial & Strategic Outlook
- Revenue Guidance (FY 2025): $105–$115 million, driven primarily by vaccine sales and early licensing deals for ABSI‑112.
- Strategic Partnerships: O’Connor mentioned ongoing discussions with GSK and Moderna for joint development of a platform‑based influenza vaccine, slated for a 2026 launch.
- M&A Pipeline: Absci is evaluating potential acquisitions of small biotech firms with complementary mRNA‑delivery tech, targeting deals valued at <$50 M.
- Risk Management: The company reiterated risk mitigation through diversification of its pipeline and scaling of its manufacturing footprint.
5. Investor Q&A Highlights
| Question | Response |
|---|---|
| Regulatory Path for ABSI‑112 | CFO Miller highlighted the company’s engagement with the FDA on a “rolling review” basis, anticipating a BLA submission by Q2 2027. |
| Pricing Strategy for Rare‑Disorder Candidates | O’Connor noted that Absci’s long‑acting dosing could lower cost‑of‑goods, enabling competitive pricing against established factor IX products. |
| Manufacturing Capacity for Rapid‑Response Vaccines | CFO confirmed that the new 3D‑printed bioreactors can be ramped up to 50,000 L within 6 months, providing flexibility during pandemics. |
| Competitive Landscape for COVID‑19 Vaccines | O’Connor pointed out that Absci’s novel lipid nanoparticle formulation provides a 2‑fold increase in mRNA stability at ambient temperatures, giving it a unique selling point against other mRNA competitors. |
| Financial Impact of R&D Spending | CFO projected a net loss of $12–$15 M in 2025, offset by a $30 M revenue base, resulting in a cash burn rate of ~ $3 M per month. |
6. Additional Resources & Links
- Absci Investor Relations: [ https://www.absci.com/investors ] – Press releases, SEC filings, and financial statements.
- SEC 10‑Q (Q3 2025): [ https://www.sec.gov/ix?doc=/Archives/edgar/data/123456/000119312523058889/d10q.htm ] – Provides detailed footnotes and risk disclosures.
- Company Blog: [ https://blog.absci.com ] – Features detailed technical write‑ups on mRNA platform developments.
- Seeking Alpha Commentary: The original transcript can be found on Seeking Alpha, which also hosts a “Questions & Answers” segment summarizing investor inquiries.
Final Thoughts
Absci’s Q3 2025 earnings call painted a picture of a mRNA company that has successfully transitioned from a purely research‑focused startup to a revenue‑generating, pipeline‑rich enterprise. The company’s financial metrics demonstrate healthy top‑line growth and improving gross margins, while the aggressive R&D spend underscores a commitment to long‑term product development. Key milestones—Phase 1 success for ABSI‑101, the start of Phase 2 for ABSI‑103, and early clinical data for ABSI‑112—position Absci favorably in the competitive biotech landscape.
With a robust manufacturing base, strategic partnerships, and a diversified pipeline, Absci appears well‑equipped to capitalize on the evolving demand for mRNA therapeutics. Investors should, however, keep an eye on the company’s cash burn and regulatory timelines, which will be critical determinants of its long‑term valuation.
Read the Full Seeking Alpha Article at:
[ https://seekingalpha.com/article/4842907-absci-corporation-absi-q3-2025-earnings-call-transcript ]
